MedTrace Logo

Clopidogrel Resistance in Stroke Patients From Different Ethnicities

NCT03806894 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-07-10

No results posted yet for this study

Summary

Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events. The aim of the present study is to evaluate the incidence of clopidogrel resistance in ischemic stroke patients from different ethnicities in Northern Israel and to find different strategies to overcome high platelet reactivity including clopidogrel dose adjustment or the choice of alternative agents. Quantification of platelet aggregation will be determined by vasodilator stimulated phosphoprotein (VASP) assay.

Conditions

Interventions

DIAGNOSTIC_TEST

Quantification of platelet aggregation

Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay

Sponsors & Collaborators

  • Ziv Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-10-31
Completion
2020-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03806894 on ClinicalTrials.gov